Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy.
Identifieur interne : 001C90 ( PubMed/Checkpoint ); précédent : 001C89; suivant : 001C91Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy.
Auteurs : Maria Stamelou [Allemagne] ; Andreas Matusch ; David Elmenhorst ; René Hurlemann ; Karla M. Eggert ; Karl Zilles ; Wolfgang H. Oertel ; Günter U. Höglinger ; Andreas BauerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Brain Mapping, Corpus Striatum (metabolism), Corpus Striatum (radionuclide imaging), Female, Fluorine Radioisotopes (metabolism), Humans, Ketanserin (analogs & derivatives), Ketanserin (metabolism), Magnetic Resonance Imaging (methods), Male, Middle Aged, Movement Disorders (etiology), Movement Disorders (pathology), Movement Disorders (radionuclide imaging), Positron-Emission Tomography (methods), Receptor, Serotonin, 5-HT2A (metabolism), Statistics as Topic, Substantia Nigra (metabolism), Substantia Nigra (radionuclide imaging), Supranuclear Palsy, Progressive (complications), Supranuclear Palsy, Progressive (radionuclide imaging), Up-Regulation (physiology).
- MESH :
- chemical , analogs & derivatives : Ketanserin.
- chemical , metabolism : Fluorine Radioisotopes, Ketanserin, Receptor, Serotonin, 5-HT2A.
- complications : Supranuclear Palsy, Progressive.
- etiology : Movement Disorders.
- metabolism : Corpus Striatum, Substantia Nigra.
- methods : Magnetic Resonance Imaging, Positron-Emission Tomography.
- pathology : Movement Disorders.
- physiology : Up-Regulation.
- radionuclide imaging : Corpus Striatum, Movement Disorders, Substantia Nigra, Supranuclear Palsy, Progressive.
- Aged, Brain Mapping, Female, Humans, Male, Middle Aged, Statistics as Topic.
Abstract
A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT(2A)) receptor ligand [18F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT(2A) receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT(2A) receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.
DOI: 10.1002/mds.22533
PubMed: 19353726
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19353726Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy.</title><author><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich, Jülich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich, Jülich</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Juliers</settlement></placeName></affiliation></author><author><name sortKey="Matusch, Andreas" sort="Matusch, Andreas" uniqKey="Matusch A" first="Andreas" last="Matusch">Andreas Matusch</name></author><author><name sortKey="Elmenhorst, David" sort="Elmenhorst, David" uniqKey="Elmenhorst D" first="David" last="Elmenhorst">David Elmenhorst</name></author><author><name sortKey="Hurlemann, Rene" sort="Hurlemann, Rene" uniqKey="Hurlemann R" first="René" last="Hurlemann">René Hurlemann</name></author><author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M" last="Eggert">Karla M. Eggert</name></author><author><name sortKey="Zilles, Karl" sort="Zilles, Karl" uniqKey="Zilles K" first="Karl" last="Zilles">Karl Zilles</name></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H" last="Oertel">Wolfgang H. Oertel</name></author><author><name sortKey="Hoglinger, Gunter U" sort="Hoglinger, Gunter U" uniqKey="Hoglinger G" first="Günter U" last="Höglinger">Günter U. Höglinger</name></author><author><name sortKey="Bauer, Andreas" sort="Bauer, Andreas" uniqKey="Bauer A" first="Andreas" last="Bauer">Andreas Bauer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22533</idno><idno type="RBID">pubmed:19353726</idno><idno type="pmid">19353726</idno><idno type="wicri:Area/PubMed/Corpus">001D61</idno><idno type="wicri:Area/PubMed/Curation">001D61</idno><idno type="wicri:Area/PubMed/Checkpoint">001C90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy.</title><author><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich, Jülich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich, Jülich</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Juliers</settlement></placeName></affiliation></author><author><name sortKey="Matusch, Andreas" sort="Matusch, Andreas" uniqKey="Matusch A" first="Andreas" last="Matusch">Andreas Matusch</name></author><author><name sortKey="Elmenhorst, David" sort="Elmenhorst, David" uniqKey="Elmenhorst D" first="David" last="Elmenhorst">David Elmenhorst</name></author><author><name sortKey="Hurlemann, Rene" sort="Hurlemann, Rene" uniqKey="Hurlemann R" first="René" last="Hurlemann">René Hurlemann</name></author><author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M" last="Eggert">Karla M. Eggert</name></author><author><name sortKey="Zilles, Karl" sort="Zilles, Karl" uniqKey="Zilles K" first="Karl" last="Zilles">Karl Zilles</name></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H" last="Oertel">Wolfgang H. Oertel</name></author><author><name sortKey="Hoglinger, Gunter U" sort="Hoglinger, Gunter U" uniqKey="Hoglinger G" first="Günter U" last="Höglinger">Günter U. Höglinger</name></author><author><name sortKey="Bauer, Andreas" sort="Bauer, Andreas" uniqKey="Bauer A" first="Andreas" last="Bauer">Andreas Bauer</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Brain Mapping</term><term>Corpus Striatum (metabolism)</term><term>Corpus Striatum (radionuclide imaging)</term><term>Female</term><term>Fluorine Radioisotopes (metabolism)</term><term>Humans</term><term>Ketanserin (analogs & derivatives)</term><term>Ketanserin (metabolism)</term><term>Magnetic Resonance Imaging (methods)</term><term>Male</term><term>Middle Aged</term><term>Movement Disorders (etiology)</term><term>Movement Disorders (pathology)</term><term>Movement Disorders (radionuclide imaging)</term><term>Positron-Emission Tomography (methods)</term><term>Receptor, Serotonin, 5-HT2A (metabolism)</term><term>Statistics as Topic</term><term>Substantia Nigra (metabolism)</term><term>Substantia Nigra (radionuclide imaging)</term><term>Supranuclear Palsy, Progressive (complications)</term><term>Supranuclear Palsy, Progressive (radionuclide imaging)</term><term>Up-Regulation (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ketanserin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Fluorine Radioisotopes</term><term>Ketanserin</term><term>Receptor, Serotonin, 5-HT2A</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetic Resonance Imaging</term><term>Positron-Emission Tomography</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Up-Regulation</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Corpus Striatum</term><term>Movement Disorders</term><term>Substantia Nigra</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Brain Mapping</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Statistics as Topic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT(2A)) receptor ligand [18F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT(2A) receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT(2A) receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19353726</PMID><DateCreated><Year>2009</Year><Month>06</Month><Day>29</Day></DateCreated><DateCompleted><Year>2009</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy.</ArticleTitle><Pagination><MedlinePgn>1170-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22533</ELocationID><Abstract><AbstractText>A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT(2A)) receptor ligand [18F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT(2A) receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT(2A) receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.</AbstractText><CopyrightInformation>(c) 2009 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stamelou</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich, Jülich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matusch</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Elmenhorst</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hurlemann</LastName><ForeName>René</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Eggert</LastName><ForeName>Karla M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Zilles</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Oertel</LastName><ForeName>Wolfgang H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Höglinger</LastName><ForeName>Günter U</ForeName><Initials>GU</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>5015H744JQ</RegistryNumber><NameOfSubstance UI="C071983">altanserin</NameOfSubstance></Chemical><Chemical><RegistryNumber>97F9DE4CT4</RegistryNumber><NameOfSubstance UI="D007650">Ketanserin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001931">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005462">Fluorine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007650">Ketanserin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D044402">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013223">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013494">Supranuclear Palsy, Progressive</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22533</ArticleId><ArticleId IdType="pubmed">19353726</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>District de Cologne</li><li>Rhénanie-du-Nord-Westphalie</li></region><settlement><li>Juliers</li></settlement></list><tree><noCountry><name sortKey="Bauer, Andreas" sort="Bauer, Andreas" uniqKey="Bauer A" first="Andreas" last="Bauer">Andreas Bauer</name><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M" last="Eggert">Karla M. Eggert</name><name sortKey="Elmenhorst, David" sort="Elmenhorst, David" uniqKey="Elmenhorst D" first="David" last="Elmenhorst">David Elmenhorst</name><name sortKey="Hoglinger, Gunter U" sort="Hoglinger, Gunter U" uniqKey="Hoglinger G" first="Günter U" last="Höglinger">Günter U. Höglinger</name><name sortKey="Hurlemann, Rene" sort="Hurlemann, Rene" uniqKey="Hurlemann R" first="René" last="Hurlemann">René Hurlemann</name><name sortKey="Matusch, Andreas" sort="Matusch, Andreas" uniqKey="Matusch A" first="Andreas" last="Matusch">Andreas Matusch</name><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H" last="Oertel">Wolfgang H. Oertel</name><name sortKey="Zilles, Karl" sort="Zilles, Karl" uniqKey="Zilles K" first="Karl" last="Zilles">Karl Zilles</name></noCountry><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001C90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:19353726
|texte= Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19353726" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |